S. Aliberti (Milan, Italy), A. Anzueto (San Antonio, United States of America)
Changes in pathogens and pneumococcal serotypes causing community-acquired pneumonia in The Netherlands S. Vestjens (Nieuwegein, Netherlands)
| |
Genetic Analyses of Multidrug-Resistant Streptococcus pneumoniae Serogroup 19 CC320/271 Clone in China J. Zhang (Shanghai, China)
| |
Impact of pneumococcal vaccination in children in the distribution of serotypes in bacteriemic pneumococcal pneumonia in adults A. ARTARAZ (Galdakao (Bizkaia), Spain)
| |
Efficiency of specific prevention of pneumococcal infection at patients from risk groups in Krasnoyarsk region A. Kraposhina (Krasnoyarsk, Russian Federation)
| |
Effectiveness data on prevention of COPD exacerbations with 13-valent pneumococal conjugate vaccine (PCV13) J. Gonzalez Ruiz (Salamanca, Spain)
| |
Pneumococcal vaccination in interstitial lung disease patients receiving systemic immunosuppressive treatment K. Kuronuma (Sapporo, Japan)
| |
Efficacy of vaccination to prevent pneumococcal infection in organized communities I. Shubin (Moscow, Russian Federation)
| |
Effectiveness of the 23-valent pneumococcal polysaccharide vaccine for the patients with lung comorbidities; a single center, retrospective, self-controlled case series study M. Aoshima (Kamogawa, Japan)
| |
A randomized, open-label, parallel design study to compare the immunogenicity of simultaneous administration versus sequential administration of quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine in the elderly K. Nakashima (Kamogawa, Japan)
| |
Osteopontin role in community-Acquired Pneumonia (CAP). R. Sharshar (Tanta, Egypt)
| |
Association between biomarkers at discharge and risk of readmission after community-acquired pneumonia – a retrospective cohort study P. Petersen (København, Denmark)
| |
Interpretation of biomarkers at emergency department depends on onset of symptoms in community-acquired pneumonia R. Méndez (VALENCIA, Spain)
| |
Diagnosis on community-acquired pneumonia (CAP) in patients with congestive heart failure (CHF) S. Avdeev (Moscow, Russian Federation)
| |
Intrahospital cardiovascular complications in severe community-acquired pneumonia A. Cilli (Antalya, Turkey)
| |
NON BACTERIEMIC PNEUMOCOCCAL PNEUMONIA: GENERAL CHARACTERISTICS AND PREDISPOSING FACTORS FOR POOR OUTCOME L. Serrano Fernandez (Bilbao (Bizkaia), Spain)
| |
Inter-hospital variation in resource utilization of diagnostic and follow-up biomarkers in adult community-acquired pneumonia S. Vestjens (Nieuwegein, Netherlands)
| |
Studying the association between mortality in patients requiring hospital admission for Community Acquired Pneumonia and pre-hospital antibiotic treatment in primary care B. Chakrabarti (Liverpool, United Kingdom)
| |